Targeting chemosensitizing doses of toremifene based on protein binding.
about
Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line.High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies.
P2860
Targeting chemosensitizing doses of toremifene based on protein binding.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Targeting chemosensitizing doses of toremifene based on protein binding.
@en
type
label
Targeting chemosensitizing doses of toremifene based on protein binding.
@en
prefLabel
Targeting chemosensitizing doses of toremifene based on protein binding.
@en
P2093
P356
P1476
Targeting chemosensitizing doses of toremifene based on protein binding.
@en
P2093
M W DeGregorio
V D Emshoff
P2888
P304
P356
10.1007/BF00686157
P577
1993-01-01T00:00:00Z
P6179
1000049909